Gefitinib in patients with brain metastases from non-small-cell lung cancer: Review of 15 clinical cases

Clinical Lung Cancer

Volumn 6, Issue 2, 2004, Pages 123-128

  Namba, Yoshinobu ^a   Kijima, Takashi ^a,b   Yokota, Soichiro ^a   Niinaka, Manabu ^a   Kawamura, Satoko ^a   Iwasaki, Takeo ^a   Takeda, Yoshito ^a   Kimura, Hiromi ^a   Okada, Tatsuya ^a   Yamaguchi, Toshihiko ^a   Nakagawa, Masaru ^a   Okumura, Yoshitomo ^a   Maeda, Hajime ^a   Ito, Masami ^a  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Central nervous system; Epidermal growth factor receptor; Molecular targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; BRAIN METASTASIS; BRAIN TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; FEMALE; HEMIPARESIS; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT CANCER; REVIEW; VERTIGO;

EID: 7444234824     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.026     Document Type: Article

References (34)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.
2. Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6:1474-1480.
3. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 1999; 10:753-759.
4. Law A, Karp DD, Dipetrillo T et al. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non-small cell lung carcinoma. Cancer 2001; 92:160-164.
5. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol 2003; 30:30-38.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
7. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3496-3502.
8. Cappuzzo F, Calandri C, Bartolini S, et al. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 2003; 89:246-247.
9. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41:227-231.
10. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003; 14:656-658.
11. Fujiwara K, Kiura K, Ueoka H, et al. Dramatic effect of ZD1839 (Iressa) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40:73-76.
12. Haringhuizen A, van Tinteren H, Vaessen HF, et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004; 15:786-792.
13. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042-1047.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
15. Regina A, Demeule M, Laplante A, et al. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 2001; 20:13-25.
16. Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 2002; 38:339-348.
17. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 3:53-57.
18. Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982; 42:2474-2479.
19. Minotti V, Crino L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998; 20:93-98.
20. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 2002; 20:293-302.
21. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 1988; 48:3478-3484.
22. Reijneveld JC, Voest EE, Taphoorn MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 2000; 247:597-608.
23. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
24. Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res 2001; 21:4373-4382.
25. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60:4959-4967.
26. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997; 16:750-759.
27. Huang SM, Li J, Armstrong EA, et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002; 62:4300-4306.
28. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-2560.
29. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7:1459-1465.
30. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-265.
31. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3250-3258.
32. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
33. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
34. Williams KJ, Telfer BA, Stratford IJ, et al. ZD1839 (Iressa), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86:1157-1161.